Because the majority of patients with diffuse brain injury are not suitable candidates for surgery, neuroprotective agents are of great importance.
It has been reported that apolipoprotein E (138) mimetic peptide can cross the blood-brain barrier in both the normal and injured brain. However, its impact on neurological function following diffuse brain injury is still unclear.
These researchers found that apolipoprotein E-derived therapeutic peptide (0.6mg/kg and 1.2mg/kg) improved synaptic stability and improved learning and memory performance after diffuse brain injury. Furthermore, apolipoprotein E mimetic peptide protected against brain injury by reducing oxidative stress, thereby suppressing the ERK1/2-Bax mitochondrial apoptotic pathway and decreasing neuronal death.
These results have been published in Neural Regeneration Research (Vol. 9, No. 5, 2014).